Extracorporeal support for patients with acute and acute on chronic liver failure

  title={Extracorporeal support for patients with acute and acute on chronic liver failure},
  author={Jonathan Aron and Banwari Agarwal and Andrew Davenport},
  journal={Expert Review of Medical Devices},
  pages={367 - 380}
ABSTRACT The number of patients developing liver failure; acute on chronic liver failure and acute liver failure continues to increase, along with the demand for donor livers for transplantation. As such there is a clinical need to develop effective extracorporeal devices to support patients with acute liver failure or acute-on-chronic liver failure to allow time for hepatocyte regeneration, and so avoiding the need for liver transplantation, or to bridge the patient to liver transplantation… 
Plasmapheresis Combined with Continuous Plasma Filtration Adsorption Rescues Severe Acute Liver Failure in Wilson’s Disease before Liver Transplantation
The experience of this case points to that plasmapheresis combined with CPFA treatment can improve clinical symptoms and bridge children over through Wilsonian crisis to late live transplantation, andCPFA treatment is feasible and safe in children weighing more than 20 kg.
The efficacy of extracorporeal membrane oxygenation in liver transplantation from non-heart-beating donors
ECMO makes 1-year patient survival acceptable in NHBDs recipients, and the risks to develop PNF and ischemic cholangiopathy were increased among NH BDs recipients.
Alleviating liver failure conditions using an integrated hybrid cryogel based cellular bioreactor as a bioartificial liver support
In conclusion, integrating the plasmapheresis and adsorbent units with the bioreactor module in one compact design improves the efficacy of the bioartificial liver device.
Intensive Care Management of Children with Liver Disease
Children with liver disease almost invariably require an admission to pediatric intensive care unit (PICU) during their life. The most common causes are (1) an acute decompensation in a patient with
Bile acid kinetic modeling in end-stage liver support patients
Abstract Background & Aims Solute generation rates, distribution volumes and compartment effects control the in vivo efficiency of any extracorporeal therapy such as extracorporeal liver support
Bile cast nephropathy: A case report and review of the literature.
The case of bile cast nephropathy and the therapeutic measures undertaken in a middle-aged male with chronic renal insufficiency that developed hyperbilirubinemia and drug-induced liver injury secondary to antibiotic use is reported.
Characterization of an Artificial Liver Support System-Related Vasovagal Reaction
A vasovagal reaction (VVR) is a rare complication in patients with severe liver injury undergoing ALSS treatment and is the main characteristics of a VVR.
Tissue engineering bioreactors have been used in order to achieve production of artificial tissue, increasing cell proliferation capacity and yield and/or in vitro tissue/disease modelling. Although
Role of Bioreactor Technology in Tissue Engineering for Clinical Use and Therapeutic Target Design
This review considers the key elements necessary to enable bioreactors to address three main areas associated with biological systems: understanding the pathophysiology of disease at the molecular level; defining possible therapeutic targets; and enabling appropriate pharmaceutical testing on a truly representative organoid.
Bilirubin detoxification using different phytomaterials: characterization and in vitro studies
Background Activated carbon (AC) is a common adsorbent that is used in both artificial and bioartificial liver devices. Methods Three natural materials – date pits of Phoenix dactylifera (fruit),


Extracorporeal Liver Support
The current state of the art and existing data on the use of extracorporeal liver support devices to treat patients with liver failure are described.
Extracorporeal liver assist device to exchange albumin and remove endotoxin in acute liver failure: Results of a pivotal pre-clinical study
The survival benefit and lack of adverse effects would support clinical trials of University College London-Liver Dialysis Device in acute liver failure patients.
Clinical extracorporeal hybrid liver support – phase I study with primary porcine liver cells
Evaluating the feasibility and safety of a hybrid liver support system with extracorporeal plasma separation and bioreactor perfusion in patients with acute liver failure who had already fulfilled the criteria for high urgency liver transplantation (LTx) found it safe and well‐tolerated.
A Novel Plasma Filtration Therapy for Hepatic Failure: Preclinical Studies
Treatment of pigs with experimentally‐induced fulminant hepatic failure is safe and effective in extending survival time and arresting brain swelling and Selective plasma filtration is a novel approach to blood purification therapy designed to reduce the level of circulating toxins of hepatic and renal failure.
Pilot‐controlled trial of the extracorporeal liver assist device in acute liver failure
Assessment of additive function for the device revealed an improvement in galactose elimination capacity after 6 hours of haemoperfusion, and better indices of prognosis will be required, in addition to those used to select for transplantation, if patients at an earlier stage of clinical deterioration are to be included in future studies.
Extracorporeal blood detoxification by sorbents in treatment of hepatic encephalopathy.
  • S. Ash
  • Medicine
    Advances in renal replacement therapy
  • 2002
Clinical results of daily MARS treatments of patients with hepatic failure are similar to that of Liver Dialysis, with neurologic and physical improvement occurs in most patients with AHE, and improved outcome for patientsWith A-on-C.
Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation.
The HepatAssist 2000 is well tolerated, improves cerebral function, and may be used as a bridge to transplantation for patients with liver failure.
Albumin Dialysis in Liver Failure: Comparison of Molecular Adsorbent Recirculating System and Single Pass Albumin Dialysis—A Retrospective Analysis
This retrospective analysis suggests equal efficacy of MARS and SPAD; however, prospective assessment to further define the role of SPAD in the treatment of acute or acute‐on‐chronic liver failure is needed.
The Prometheus® Device for Extracorporeal Support of Combined Liver and Renal Failure
Prompt liver detoxification was supported by a significant decrease of serum levels of conjugated bilirubin, bile acids and ammonia, and Prometheus is a safe treatment for patients with HRS.
Prospective, Randomized, Multicenter, Controlled Trial of a Bioartificial Liver in Treating Acute Liver Failure
This is the first prospective, randomized, controlled trial of an extracorporeal liver support system, demonstrating safety and improved survival in patients with fulminant/subfulminant hepatic failure.